Considerations for the Conduct of Clinical Trials of Medical Products During Major Disruptions Due to Disasters and Public Health Emergencies
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
September 21, 2023
October 4, 2023
c8517058-2a59-4ca3-be07-e0046663793f
Related Documents
Reformulating Drug Products That Contain Carbomers Manufactured With Benzene
Guidance DocumentDecember 28, 2023Center for Drug Evaluation and Research
Certain Ophthalmic Products: Policy Regarding Compliance With 21 CFR Part 4 Guidance for Industry: Guidance for Industry
Guidance DocumentMarch 22, 2022Center for Drug Evaluation and Research
Institutional Review Board (IRB) Review of Individual Patient Expanded Access Submissions for Investigational Drugs and Biological Products: Guidance for IRBs and Clinical Investigators
Guidance DocumentSeptember 11, 2023Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox